GORDON CARL L — SEC Form 4 filings
SEC reporting owner CIK 1282930. 27 Form 4 filings on record with FilingPulse; latest filed 2026-08-12.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2024-01-26 to 2026-08-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 6 filings — 6,135,116 shares, $54,520,748 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 4 filings — 3,901,936 shares, $17,251,990 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 70.
- Largest priced transaction: purchase of 1,000,000 shares @ $15.00 ($15,000,000) in Scribe Therapeutics, Inc., filed 2026-07-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Scribe Therapeutics, Inc. (SCTX) | Director | 2 | 1 leg · 1,000,000 sh · $15,000,000 | — | 3 |
| MBX Biosciences, Inc. (MBX) | Director, 10% owner | 3 | 6 legs · 940,672 sh · $14,020,756 | — | 6 |
| Keros Therapeutics, Inc. (KROS) | Director | 4 | — | 2 legs · 250,000 sh · $11,002,500 | 5 |
| BlossomHill Therapeutics, Inc. (BLSM) | Director | 2 | 1 leg · 625,000 sh · $10,000,000 | — | 5 |
| ArriVent Biopharma, Inc. (AVBP) | Director, 10% owner | 1 | 2 legs · 444,444 sh · $7,999,992 | — | 8 |
| Adicet Bio, Inc. (ACET) | Director, 10% owner | 3 | 3 legs · 3,125,000 sh · $7,500,000 | — | 10 |
| Compass Therapeutics, Inc. (CMPX) | Director | 4 | — | 1 leg · 3,571,428 sh · $5,678,571 | 3 |
| Terns Pharmaceuticals, Inc. (TERN) | Director, 10% owner | 3 | — | 6 legs · 56,164 sh · $561,640 | 2 |
| BiomX Inc. (PHGE) | 10% owner | 2 | — | 1 leg · 24,344 sh · $9,280 | 4 |
| Lomond Therapeutics Holdings, Inc. | Director | 1 | — | — | 13 |
+2 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — GORDON CARL L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | BlossomHill Therapeutics, Inc. (BLSM) | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | BlossomHill Therapeutics, Inc. (BLSM) | Grant/award (A): 23,904 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Scribe Therapeutics, Inc. (SCTX) | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Scribe Therapeutics, Inc. (SCTX) | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-06-06 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Compass Therapeutics, Inc. (CMPX) | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-02-13 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-09-13 | 4 | MBX Biosciences, Inc. (MBX) | Grant/award (A): 15,963 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Adicet Bio, Inc. (ACET) | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-15 | 4 | Keros Therapeutics, Inc. (KROS) | Sale (S): 220,600 @ $44.01 · Sale (S): 29,400 @ $44.01 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Sale (S): 39,433 @ $10 · Sale (S): 5,401 @ $10 · Sale (S): 6,142 @ $10 · Sale (S): 4,009 @ $10 · Sale (S): 556 @ $10 · Sale (S): 623 @ $10 | EDGAR |
| 2024-07-02 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 4,676 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., Chimovits Erez | Option exercise/expiry (X): 9,280,408 @ $0.24 · Sale (S): 24,344 @ $0.38 · Option exercise/expiry (X): 9,280,408 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 · Disposition to issuer (D): 40,501 (derivative) · +2 more | EDGAR |
| 2024-03-19 | 4 | BiomX Inc. (PHGE) jointly with OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., Chimovits Erez | Purchase (P): 4,327 (derivative) · Purchase (P): 2,163,500 (derivative) | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Code (U): 17,063,000 · Code (U): 650,600 · Disposition to issuer (D): 3,250 (derivative) | EDGAR |
| 2024-02-14 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | ArriVent Biopharma, Inc. (AVBP) | Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 more | EDGAR |
| 2024-01-26 | 4 | Adicet Bio, Inc. (ACET) | Purchase (P): 1,841,100 @ $2.40 · Purchase (P): 242,200 @ $2.40 · Purchase (P): 1,041,700 @ $2.40 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1282930 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →